Search results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 6 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express ...
Your expert guide to melanomas and how to spot them
The Telegraph via Yahoo News· 4 days agoIf you have noticed a lingering spot somewhere on your skin, it would be wise not to dismiss it, especially if there’s something unusual about its...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 6 days agoThe investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9%...
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 4 days agoThe adjustment followed HOOKIPA Pharma's announcement regarding the trial design of a Phase 2/3...
Harry Jowsey reveals skin cancer diagnosis at age 26 — here’s what to know about the ‘scary’ disease
NY Post via Yahoo News· 2 days agoGetty Images The Centers for Disease Control and Prevention say that sun safety is key to reduce the...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 14 hours agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its...
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 4 days ago(NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the final design for its...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoBladder cancer and renal cell carcinoma are big opportunities, Issi said, with between 82,000 to...
Immutep Shares Rise 12% After Positive Data From Eftilagimod Trial
Market Watch· 6 days agoImmutep Limited shares were up 12% at $2.82 after the company said it saw positive preliminary topline results from its Phase IIb trial evaluating eftilagimod alpha, or efti, in combination ...
EU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE)
Seeking Alpha· 7 days agoEU regulators have approved BeiGene’s (NASDAQ:BGNE) tislelizumab for the treatment of three types of...